- Home
- RBOT vs IKNA Comparison
RBOT vs IKNA Comparison
Compare RBOT & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- IKNA
- Stock Information
- Founded
- RBOT 2014
- IKNA 2016
- Country
- RBOT United States
- IKNA United States
- Employees
- RBOT N/A
- IKNA N/A
- Industry
- RBOT Medical Specialities
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- RBOT Health Care
- IKNA Health Care
- Exchange
- RBOT Nasdaq
- IKNA Nasdaq
- Market Cap
- RBOT 94.2M
- IKNA 79.6M
- IPO Year
- RBOT N/A
- IKNA 2021
- Fundamental
- Price
- RBOT $13.99
- IKNA $1.61
- Analyst Decision
- RBOT Hold
- IKNA Buy
- Analyst Count
- RBOT 2
- IKNA 2
- Target Price
- RBOT $10.25
- IKNA $3.00
- AVG Volume (30 Days)
- RBOT 53.0K
- IKNA 99.7K
- Earning Date
- RBOT 11-12-2024
- IKNA 11-07-2024
- Dividend Yield
- RBOT N/A
- IKNA N/A
- EPS Growth
- RBOT N/A
- IKNA N/A
- EPS
- RBOT N/A
- IKNA N/A
- Revenue
- RBOT N/A
- IKNA $659,000.00
- Revenue This Year
- RBOT N/A
- IKNA N/A
- Revenue Next Year
- RBOT N/A
- IKNA N/A
- P/E Ratio
- RBOT N/A
- IKNA N/A
- Revenue Growth
- RBOT N/A
- IKNA N/A
- 52 Week Low
- RBOT $4.27
- IKNA $1.22
- 52 Week High
- RBOT $21.42
- IKNA $2.30
- Technical
- Relative Strength Index (RSI)
- RBOT 55.36
- IKNA 35.62
- Support Level
- RBOT $12.53
- IKNA $1.56
- Resistance Level
- RBOT $16.55
- IKNA $1.71
- Average True Range (ATR)
- RBOT 1.89
- IKNA 0.05
- MACD
- RBOT -0.29
- IKNA -0.01
- Stochastic Oscillator
- RBOT 26.25
- IKNA 31.58
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.